CO5611109A2 - Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2 - Google Patents

Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2

Info

Publication number
CO5611109A2
CO5611109A2 CO04079024A CO04079024A CO5611109A2 CO 5611109 A2 CO5611109 A2 CO 5611109A2 CO 04079024 A CO04079024 A CO 04079024A CO 04079024 A CO04079024 A CO 04079024A CO 5611109 A2 CO5611109 A2 CO 5611109A2
Authority
CO
Colombia
Prior art keywords
delta
cyclooxygenasa
alfa
binding
combinations
Prior art date
Application number
CO04079024A
Other languages
English (en)
Spanish (es)
Inventor
Taylor Charles Price Jr
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5611109A2 publication Critical patent/CO5611109A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CO04079024A 2002-02-22 2004-08-13 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2 CO5611109A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35929502P 2002-02-22 2002-02-22
US40436502P 2002-08-19 2002-08-19

Publications (1)

Publication Number Publication Date
CO5611109A2 true CO5611109A2 (es) 2006-02-28

Family

ID=27760521

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04079024A CO5611109A2 (es) 2002-02-22 2004-08-13 Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2

Country Status (21)

Country Link
US (1) US20030199567A1 (https=)
EP (1) EP1480639A1 (https=)
JP (1) JP2005523281A (https=)
KR (1) KR20040085216A (https=)
CN (1) CN1635887A (https=)
AR (1) AR038531A1 (https=)
AU (1) AU2003246864A1 (https=)
BR (1) BR0307906A (https=)
CA (1) CA2476438A1 (https=)
CO (1) CO5611109A2 (https=)
HN (1) HN2003000071A (https=)
IL (1) IL162932A0 (https=)
MX (1) MXPA04008175A (https=)
NO (1) NO20043947L (https=)
PA (1) PA8567201A1 (https=)
PE (1) PE20031052A1 (https=)
PL (1) PL372210A1 (https=)
RU (1) RU2286151C2 (https=)
TW (1) TW200303214A (https=)
UY (1) UY27675A1 (https=)
WO (1) WO2003070237A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303041B2 (en) * 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
US7169812B2 (en) 2003-07-01 2007-01-30 Medtronic, Inc. Process for producing injectable gabapentin compositions
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
WO2005041976A2 (en) * 2003-10-23 2005-05-12 Medtronic, Inc. Injectable gabapentin compositions
JP2009533368A (ja) * 2006-04-11 2009-09-17 ノバルティス アクチエンゲゼルシャフト 有機化合物
US20130012485A1 (en) * 2006-12-22 2013-01-10 Baeschlin Daniel Kaspar Organic compounds
US20090275529A1 (en) * 2008-05-05 2009-11-05 Reiss Allison B Method for improving cardiovascular risk profile of cox inhibitors
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀과 항간질제의 약제학적 병용물
KR102631399B1 (ko) * 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
CA3200132A1 (en) * 2020-10-28 2022-05-05 Tremeau Pharmaceuticals, Inc. Aqueous formulations of water insoluble cox-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234929A (en) * 1992-07-20 1993-08-10 William Chelen Method of treating motion sickness with anticonvulsants and antitussive agents
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5352638A (en) * 1994-02-22 1994-10-04 Corning Incorporated Nickel aluminosilicate glass-ceramics
AU703428B2 (en) * 1994-07-27 1999-03-25 Warner-Lambert Company Use of gabapentin in the treatment of anxiety and panic
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1999008670A1 (en) * 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
JP3782935B2 (ja) * 1997-09-08 2006-06-07 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗癲癇化合物を含有する鎮痛剤組成物およびその使用方法
NZ503980A (en) * 1997-12-16 2002-09-27 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders
US6451857B1 (en) * 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
PL351069A1 (en) * 1999-12-08 2003-03-10 Pharmacia Corp Valdecoxib compositions

Also Published As

Publication number Publication date
PA8567201A1 (es) 2003-11-12
RU2004125609A (ru) 2006-01-27
AR038531A1 (es) 2005-01-19
BR0307906A (pt) 2004-12-21
CN1635887A (zh) 2005-07-06
TW200303214A (en) 2003-09-01
PE20031052A1 (es) 2003-12-24
WO2003070237A1 (en) 2003-08-28
PL372210A1 (en) 2005-07-11
IL162932A0 (en) 2005-11-20
RU2286151C2 (ru) 2006-10-27
MXPA04008175A (es) 2004-11-26
EP1480639A1 (en) 2004-12-01
NO20043947L (no) 2004-09-21
UY27675A1 (es) 2003-09-30
HN2003000071A (es) 2003-11-24
CA2476438A1 (en) 2003-08-28
KR20040085216A (ko) 2004-10-07
AU2003246864A1 (en) 2003-09-09
JP2005523281A (ja) 2005-08-04
US20030199567A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
CO5611109A2 (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2
NO20034644D0 (no) Fettsyrer med halvlange kjeder, glycerider og analoger som neutrofile overlevelses- og aktiveringsfaktorer
CO5611113A2 (es) Tripeptidos que poseen un eter de hidroxiprolina de una quinolina sustituida para la inhibicion de ns3 (hepatitis c)
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
AR039701A1 (es) Combinaciones de compuestos activos fungicidas
CR9614A (es) Inhibidores heterobiciclicos de las metaloproteasas
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
EA200400986A1 (ru) Гетероциклические трипептиды в качестве ингибиторов вируса гепатита c
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
MX2007002236A (es) S-triazolil-alfa-mercaptoacetanilidas como inhibidores de transcriptasa inversa de virus de inmunodeficiencia humana.
CR6682A (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorios, autoinmunes y respiratorias
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
ES2187077T3 (es) Mezclas fungicidas a base de compuestos de amida.
ATE457977T1 (de) Biguanidderivate
PA8542201A1 (es) Inhibidores de pcp basados en acidos-3-heterociclilpropanohidroxamicos
JO2369B1 (en) Novel cyclohexyl sulphones
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
AR028958A1 (es) INHIBIDORES DE TRANSCRIPTASA INVERSA NO NUCLEoSIDOS
AR012048A2 (es) Derivados del acido fenil cicloalquilcarboxilicos y el uso de los mismos
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла
CO5700781A2 (es) Agonistas morfolinicos de la dopamina
AR057464A1 (es) Procedimiento para la preparacion de derivados de sulfonamida
AR042037A1 (es) Profarmaco de celecoxib
CR8340A (es) Pirazolilcarboxanilidas n-sustituidas
IT1289979B1 (it) 5-idrossimetil-6-idrossi-2-amminotetraline attive come agenti cardiovascolari

Legal Events

Date Code Title Description
FC Application refused